Martin T et al. Baseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): Results of a subset analysis of a phase 2 trial in patients with relapsed and refractory multiple myeloma (R/R MM). Proc ASH 2010;Abstract 3031.

Vij R et al. Carfilzomib: High single-agent response rate with minimal neuropathy even in high-risk patients. Proc ASH 2010;Abstract 1938.

Dr Fonseca is Consultant and Professor of Medicine at the Mayo Clinic Arizona and Deputy Director of the Mayo Clinic Cancer Center in Scottsdale, Arizona.